BIOQUAL, Inc. (OTC-Pink:BIOQ) ( www.bioqual.com ):
|
|
Nine Months Ended
|
|
Three Months Ended
|
|
|
|
February 28,
|
|
February 29,
|
|
February 28,
|
|
February 29,
|
|
|
|
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
41,070,486
|
|
$
|
32,884,055
|
|
$
|
12,584,303
|
|
$
|
11,593,217
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Before Income Tax
|
|
$
|
5,942,062
|
|
$
|
4,150,830
|
|
$
|
1,379,460
|
|
$
|
1,018,306
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
$
|
4,203,962
|
|
$
|
2,936,730
|
|
$
|
975,960
|
|
$
|
720,406
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic Earnings per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Common Stock
|
|
$
|
4.70
|
|
$
|
3.29
|
|
$
|
1.09
|
|
$
|
.81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Earnings per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Common Stock
|
|
$
|
4.70
|
|
$
|
3.29
|
|
$
|
1.09
|
|
$
|
.81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares Outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Basic Earnings Per Share
|
|
|
893,932
|
|
|
893,416
|
|
|
894,416
|
|
|
893,416
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares Outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Diluted Earnings Per Share
|
|
|
893,932
|
|
|
893,843
|
|
|
894,416
|
|
|
893,843
|
|
|
|
|
|
|
|
|
|
For more detail related to the fiscal year 2021 unaudited third quarter results, please visit our web site at www.bioqual.com .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005716/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)